Cipla Revenue History — Quarter by Quarter

Cipla's revenue moved from ₹6,329 Cr in Q1 FY24 to ₹6,541 Cr in Q4 FY26, a 3.3% change over 12 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

Quarter	Revenue (₹ Cr)	YoY Change
Q4 FY26	₹6,541 Cr	—
Q3 FY26	₹7,074 Cr	0%
Q2 FY26	₹7,589 Cr	+8%
Q1 FY26	₹6,957 Cr	+4%
Q4 FY25	₹6,730 Cr	+9%
Q3 FY25	₹7,073 Cr	+8%
Q2 FY25	₹7,051 Cr	+9%
Q1 FY25	₹6,694 Cr	+7%
Q4 FY24	₹6,163 Cr	+10%
Q3 FY24	₹6,544 Cr	+14%
Q2 FY24	₹6,678 Cr	+15%
Q1 FY24	₹6,329 Cr	+18%

What management said about revenue

Q4 FY26 · US business to reach $1B run-rate by FY27-end

Cipla targets a $1 billion annualized run-rate for US business by end of FY27, driven by respiratory and peptide launches.

Q4 FY26 · India business to deliver double-digit growth in FY27-28

Management expects strong double-digit and market-beating growth in India for FY27 and FY28.

Q4 FY26 · R&D spend to remain around 7% of sales

R&D investment will continue at approximately 7% of revenue, supporting complex generics and biosimilars pipeline.

Q3 FY26 · U.S. launches: 4 respiratory and 4 peptide assets in FY27

Pipeline includes generic Advair, two other large respiratory assets (likely Symbicort), and three peptide launches including generic Victoza.

Q2 FY26 · Generic Revlimid contribution immaterial from Q3 FY26

Revlimid revenue expected to be very small in Q3 and decline further as patent expires in January.

Q2 FY26 · Launch of four major respiratory assets by CY26

Includes generic Advair in Q4 2026 and three peptide assets including liraglutide.

Q2 FY26 · US revenue directional target of $1B next year

Run-rate expected to reach $1B in US revenue during next fiscal year, subject to approval timelines.

Q1 FY26 · US revenue target of ~$1 billion by FY27

CEO stated pipeline (including respiratory launches like generic Symbicort) should get US revenue closer to or surpass $1 billion by FY27.

Q1 FY26 · India branded business to grow in line with IPM in next three quarters

COO expressed confidence that India branded prescription business will grow at industry rates for the remaining quarters of FY26.

Q4 FY25 · Advair launch expected in FY26

Advair will be commercialized from the U.S. facility, with launch expected in FY26 depending on FDA prioritization.

Q4 FY25 · Two to three peptide launches in FY26

Cipla aims to launch two to three peptide assets in FY26, with one expected to be a large asset.

Q4 FY25 · U.S. revenue run rate of ~$220 million for Q1 FY26

Management indicated U.S. revenue for the next quarter is expected to be around $220 million, factoring in Revlimid compression.